CONGRESS ABSTRACT

Introduction Acute decompensated heart failure (ADHF) remains a leading cause of hospitalization and mortality worldwide despite therapeutic advances. Early identification of patients at increased risk of adverse outcomes is crucial to improve clinical decision-making and optimize management strategies. Although early and accelerated treatment approaches may enhance hemodynamic stabilization, their…

Background. Type 2 sodium glucose cotransporter inhibitors (SGLT2i) have demonstrated cardiorenal protection in patients affected by type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Among the mechanisms underlying this benefit, there is the possible restoration of tubuloglomerular, which contrasts glomerular hyperfiltration and the…

Background & Study Aim. The observational PONTE SC/SCA registry was designed to evaluate the effectiveness of integrated hospital-to-community care pathways for patients with heart failure (HF) or those recently hospitalized for acute coronary syndrome (ACS). This study aimed to describe the baseline characteristics of patients with HF enrolled in…

Background & Study Aim. In patients with heart failure with reduced ejection fraction (HFrEF), the use of four main pharmacological classes is currently recommended: angiotensin receptor–neprilysin inhibitors (ARNI), preferred over angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium–glucose co-transporter 2 inhibitors…

Background & Study Aim. In recent years, significant progress has been made not only in the treatment of heart failure with reduced ejection fraction (HFrEF) but also in patients with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). This study aimed to evaluate the management of HFmrEF and HFpEF…

Introduction Growing evidence supports early and intensified therapy during hospitalization for acute decompensated heart failure (ADHF) to reduce cardiovascular morbidity and mortality across the entire spectrum of ejection fraction (EF). Trials such as EMPULSE and TRANSITION have demonstrated that early initiation of empagliflozin and sacubitril/valsartan in hospitalized patients with…